Jurgen Figys
Overview
When pharma and biotech companies are in need of cross-jurisdictional intellectual property/patent and regulatory advice, they trust Jurgen Figys for his understanding of the life sciences business — being trained as a biomedical scientist and seconded at pharma companies — as well as his profound knowledge of the legal IP and regulatory challenges in this field. As one of the few lawyers in Belgium also trained as a scientist, Jurgen is able to combine his scientific reasoning with his legal knowledge, a considerable asset in the technology-driven IP field.
Career & Education
- Free University of Brussels (Vrije Universiteit Brussel), M.B.M.S., magna cum laude, 2001
- Free University of Brussels (Vrije Universiteit Brussel), LL.M., cum laude, 2010
- Belgium
- Dutch
- English
- French
A pivotal force propelling the IP practice to new heights. A virtuoso in the life sciences, he is a go-to for global industry powerhouses, owing to his impressive track record in patent matters.
— IAM Patent, 2025
Jurgen's Insights
Client Alert | 5 min read | 03.22.26
EU Pharma Package: Regulatory Data Protection Compromise Proposal
In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions.
Client Alert | 2 min read | 03.12.26
Client Alert | 6 min read | 12.15.25
The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package
Client Alert | 6 min read | 11.25.25
Brussels Court Clarifies the EU’s SPC Manufacturing Waiver Regulation Rules
Recognition
- Legal 500 EMEA: Belgium, Industry Focus: Healthcare & Life Sciences, Next Generation Partner, 2024–present
- Legal 500 EMEA: Belgium, EU Regulatory: Pharma, Medical Devices & Biotech, Leading Partner, 2025
- IAM Patent 1000: Litigation and Transactions, Silver, 2023–present
- Managing Intellectual Property IP Stars: Notable Practitioner, 2025
Jurgen's Insights
Client Alert | 5 min read | 03.22.26
EU Pharma Package: Regulatory Data Protection Compromise Proposal
In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions.
Client Alert | 2 min read | 03.12.26
Client Alert | 6 min read | 12.15.25
The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package
Client Alert | 6 min read | 11.25.25
Brussels Court Clarifies the EU’s SPC Manufacturing Waiver Regulation Rules
Insights
Counterfeit Seizures Proceedings in Belgium – An Update
|08.29.17
Cahiers Antwerp Brussels Ghent
Jouer avec les limites de l'usage off-label?
|02.13.15
Le Journal du Médecin 2394, 39
De Minimis in Belgian Patent Law
|01.01.15
I.R.D.I.
De exclusieve bevoegdheid van de rechtbank van koophandel en het hof van beroep te Brussel in het nieuwe Wetboek intellectuele eigendom (Boek XI van het WER)
|12.26.14
RABG
Practices
- Intellectual Property — Brussels Practice
- Life Sciences — Brussels Practice
- Dispute Resolution — Brussels Practice
- Intellectual Property Litigation
- Litigation and Trial
- Regulatory — Brussels Practice
- Intellectual Property
- European IP Law
- Patent Litigation
- Copyright — Brussels Practice
- Trademarks and Designs — Brussels Practice
- Health Care
- Digital Health and Health Information Technology
- Product Compliance, Risk Management and Advertising — Brussels Practice
- Life Sciences — Intellectual Property
- Life Sciences
Industries
Jurgen's Insights
Client Alert | 5 min read | 03.22.26
EU Pharma Package: Regulatory Data Protection Compromise Proposal
In our second alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission (Commission), the European Parliament (Parliament), and the Council of the European Union (Council) on one of the most debated and anxiously anticipated topics, the regulatory data protection (RDP). While all EU institutions proposed a modulation system, they differed significantly in terms of the baseline period and the structure of the possible extensions.
Client Alert | 2 min read | 03.12.26
Client Alert | 6 min read | 12.15.25
The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package
Client Alert | 6 min read | 11.25.25
Brussels Court Clarifies the EU’s SPC Manufacturing Waiver Regulation Rules




